Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AGEN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer NCT05608044 · Metastatic Colorectal Cancer Botensilimab, Balstilimab | AGEN Agenus Inc. | Phase 2 | Active, not recruiting | 234 | Sep 2027 | Registry ↗ |
| Nov 4, 2026 | Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) NCT05572970 · Cancer Balstilimab, Zalifrelimab | AGEN Agenus Inc. | — | Available | — | — | Registry ↗ |
| Oct 19, 2026 | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma NCT05529316 · Advanced Melanoma Botensilimab, Balstilimab | AGEN Agenus Inc. | Phase 2 | Terminated | 150 | Apr 27, 2026 | Registry ↗ |
| Aug 11, 2026 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Ad… NCT03495882 · Cervical Cancer Zalifrelimab, Balstilimab | AGEN Agenus Inc. | Phase 1/2 | Completed | 175 | Jul 15, 2022 | Registry ↗ |
| Jun 11, 2026 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer NCT05630183 · Metastatic Pancreatic Ductal Adenocarcinoma Botensilimab, Gemcitabine | AGEN Agenus Inc. | Phase 2 | Completed | 81 | Jan 5, 2026 | Registry ↗ |
| May 15, 2026 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Reg… NCT06751524 · Colorectal Cancer (CRC), Pancreatic Cancer Botensilimab, Balstililmab | AGEN Agenus Inc. | — | Available | — | — | Registry ↗ |
| Mar 30, 2026 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer NCT03860272 · Advanced Cancer, Angiosarcoma Botensilimab, Balstilimab | AGEN Agenus Inc. | Phase 1 | Active, not recruiting | 499 | Jan 13, 2025 | Registry ↗ |
| Mar 27, 2026 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Lin… NCT03894215 · Cervical Cancer AGEN2034, AGEN1884 | AGEN Agenus Inc. | Phase 2 | Terminated | 211 | Mar 26, 2025 | Registry ↗ |
| Oct 15, 2025 | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors NCT05025085 · Advanced Cancer AGEN1777, a PD-1 inhibitor | AGEN Agenus Inc. | Phase 1 | Completed | 25 | Jul 11, 2023 | Registry ↗ |
| Jul 30, 2025 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer NCT03104699 · Advanced Cancer, Cervical Cancer AGEN2034 | AGEN Agenus Inc. | Phase 1/2 | Completed | 211 | Jun 15, 2022 | Registry ↗ |
| Apr 30, 2025 | Study of AGEN1571 in Participants With Advanced Solid Tumors NCT05377528 · Advanced Solid Tumor AGEN1571, Balstilimab | AGEN Agenus Inc. | Phase 1 | Completed | 22 | Dec 23, 2024 | Registry ↗ |
| Mar 17, 2025 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Canc… NCT02694822 · Advanced Solid Cancers, Advanced Solid Cancers Refractory t… Zalifrelimab | AGEN Agenus Inc. | Phase 1/2 | Completed | 89 | Mar 30, 2022 | Registry ↗ |
| Jan 13, 2025 | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer NCT04121676 · Advanced Cancer AGEN2373, Botensilimab | AGEN Agenus Inc. | Phase 1 | Completed | 91 | Feb 22, 2024 | Registry ↗ |
| Mar 28, 2024 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervi… NCT05033132 · Cervical Cancer Balstilimab, Balstilimab + Zalifrelimab | AGEN Agenus Inc. | Phase 2 | Withdrawn | 0 | Dec 30, 2024 | Registry ↗ |
| Sep 28, 2023 | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma NCT00081809 · Lymphoma, Follicular, Lymphoma, Small Lymphocytic autologous human tumor-derived HSPPC-96 | AGEN Agenus Inc. | Phase 2 | Completed | 35 | Jun 2005 | Registry ↗ |
| Oct 5, 2022 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRA… NCT04943627 · Advanced Cancer, Metastatic Cervical Cancer Balstilimab (BAL), Topotecan | AGEN Agenus Inc. | Phase 3 | Withdrawn | 0 | Oct 22, 2021 | Registry ↗ |
| Mar 3, 2022 | A Study in Subjects With Advanced Solid Tumors NCT04156100 · Advanced Solid Tumor AGEN1223, AGEN1223 and balstilimab | AGEN Agenus Inc. | Phase 1 | Terminated | 19 | Apr 8, 2021 | Registry ↗ |
| Jan 11, 2022 | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma NCT04607200 · Angiosarcoma AGEN2034, AGEN1884 | AGEN Agenus Inc. | Phase 2 | Withdrawn | 0 | Sep 13, 2021 | Registry ↗ |
| Dec 2, 2021 | Phase 1a Study to Evaluate Immunogenicity of ASV® NCT03673020 · Solid Tumor, Adult ASV® AGEN2017 + QS-21 Stimulon® adjuvant | AGEN Agenus Inc. | Phase 1 | Completed | 3 | Feb 3, 2021 | Registry ↗ |
| Jul 13, 2021 | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital… NCT01687595 · Herpes Simplex Type 2 HerpV and QS-21, Placebo | AGEN Agenus Inc. | Phase 2 | Completed | 80 | Sep 2013 | Registry ↗ |
| Jun 3, 2021 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resec… NCT01147536 · Renal Cell Carcinoma HSPPC-96 | AGEN Agenus Inc. | Phase 2 | Terminated | 12 | Jun 2012 | Registry ↗ |
| Jun 2, 2020 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC NCT03411473 · NSCLC Stage IV AGEN1884 in combination with pembrolizumab | AGEN Agenus Inc. | Phase 2 | Terminated | 2 | May 1, 2018 | Registry ↗ |
| Jun 2, 2020 | Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer NCT02992977 · Advanced Cancer AutoSynVax™ vaccine | AGEN Agenus Inc. | Phase 1 | Terminated | 3 | Dec 2018 | Registry ↗ |
23 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances